These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29269300)

  • 1. MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7.
    Ping W; Gao Y; Fan X; Li W; Deng Y; Fu X
    Biochem Biophys Res Commun; 2018 Jan; 495(4):2482-2489. PubMed ID: 29269300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
    Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
    Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    Ge P; Cao L; Chen X; Jing R; Yue W
    BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer.
    Shen H; Zhu F; Liu J; Xu T; Pei D; Wang R; Qian Y; Li Q; Wang L; Shi Z; Zheng J; Chen Q; Jiang B; Shu Y
    PLoS One; 2014; 9(7):e103305. PubMed ID: 25058005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
    Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
    Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
    Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
    Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.
    Nishijima N; Seike M; Soeno C; Chiba M; Miyanaga A; Noro R; Sugano T; Matsumoto M; Kubota K; Gemma A
    Int J Oncol; 2016 Mar; 48(3):937-44. PubMed ID: 26783187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1.
    Jin S; He J; Li J; Guo R; Shu Y; Liu P
    Thorac Cancer; 2018 Oct; 9(10):1262-1270. PubMed ID: 30126075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
    Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
    J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
    Yamamoto C; Basaki Y; Kawahara A; Nakashima K; Kage M; Izumi H; Kohno K; Uramoto H; Yasumoto K; Kuwano M; Ono M
    Cancer Res; 2010 Nov; 70(21):8715-25. PubMed ID: 20959484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer.
    Zhong M; Ma X; Sun C; Chen L
    Chem Biol Interact; 2010 Mar; 184(3):431-8. PubMed ID: 20097187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16.
    Wang N; Zhang T
    Oncol Res; 2018 Aug; 26(7):1005-1014. PubMed ID: 29295721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trans-3,5,4´-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498.
    Lu M; Liu B; Xiong H; Wu F; Hu C; Liu P
    J Cell Mol Med; 2019 Apr; 23(4):2431-2441. PubMed ID: 30701693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
    Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.
    Hu FY; Cao XN; Xu QZ; Deng Y; Lai SY; Ma J; Hu JB
    J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):839-845. PubMed ID: 27924500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
    Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
    Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
    Trials; 2015 Apr; 16():146. PubMed ID: 25873045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.